BioSpace News Archive

Opdivo demonstrated a 23% reduction in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy

Approximately 28,000 neuroscience researchers, clinicians, and advocates from around the world will gather in Chicago from October 19-23 for Neuroscience 2019, the Society for Neuroscience annual meeting.

AstraZeneca and Merck’s LYNPARZA reduced the risk of disease progression or death by 51% in men with homologous recombination repair (HRR) gene mutations

The Arthroscopy Association of North America (AANA) will debut the AANA J. Whit Ewing, M.D. Simulation Room in the Orthopaedic Learning Center (OLC) with a Ribbon-Cutting Ceremony Oct. 4.

The Alliance for Safe Biologic Medicines this week shared preliminary findings from a survey of 575 biologic prescribers in six Western European countries, covering several key policy issues including biosimilar substitution practices, adverse event reporting, and government tendering criteria.

Post Acute Medical, LLC, announced it has acquired nine long-term acute care hospitals from LifeCare Holdings, which filed for bankruptcy in May.

Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today presented promising safety and efficacy data of TG4001 in combination with avelumab (BAVENCIO®), a human anti-programmed death ligand (PD-L1) antibody, in HPV-16+ recurrent or metastatic malignancies (including oropharyngeal cancers)

Lysogene, a pioneering, Phase 3, biopharmaceutical company specializing in gene therapy targeting central nervous system diseases, announced financial results and major advancements for 2019.

Moberg Pharma AB (OMX: MOB) has signed an exclusive license agreement with Taisho Pharmaceutical Co., Ltd for development, registration and commercialization of MOB-015 in Japan.

12-month initiative demonstrates improved patient care and decreased hospital costs by reducing blood culture contamination